Data Sheet (Cat.No.T16380)

TargetMol

OGT 2115

Chemical Properties



CAS No. : 853929-59-6

Formula: C24H16BrFN2O4

Molecular Weight: 495.3

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	OGT 2115 is an inhibitor of heparanase (IC50 = 0.4 μM), an enzyme that cleaves heparan sulfate into glucuronic acid (GlcUA) and N-acetylglucosamine (GlcNAc). OGT 2115 also showed antiangiogenic properties (IC50=1 μM).
Targets(IC50)	Others,glycosidase
In vitro	OGT 2115 obviously inhibits the invasion and migration induced by Adriamycin. Furthermore, the MTT assay results display that OGT 2115 does not decrease the anti-proliferative effect of Adriamycin. HeparanaseInhibitorOGT 2115 can inhibit metastasis induced by endoplasmic reticulum (ER) stress in breast cancer cells, although not significantly. The number and rate of migrated cells are significantly reduced following the exposure of the cells to Tunicamycin + OGT 2115, compared with the control group [2].
In vivo	OGT 2115 displays a plasma concentration of ~10x the heparanase IC50 following oral dosing at 20 mg/kg when administered to mice[1].

Solubility Information

Solubility	DMSO: 5.5 mg/mL (11.1 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+90% Saline: 0.56 mg/mL (1.13 mM),Suspension. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.019 mL	10.0949 mL	20.1898 mL
5 mM	0.4038 mL	2.019 mL	4.038 mL
10 mM	0.2019 mL	1.0095 mL	2.019 mL
50 mM	0.0404 mL	0.2019 mL	0.4038 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Courtney SM, et al. Furanyl-1,3-thiazol-2-yl and benzoxazol-5-yl acetic acid derivatives: novel classes of heparanase inhibitor. Bioorg Med Chem Lett. 2005 May 2;15(9):2295-9.
Li Y, et al. Suppression of endoplasmic reticulum stress-induced invasion and migration of breast cancer cells through the downregulation of heparanase. Int J Mol Med. 2013 May;31(5):1234-42.